⌘+K

Post-results note

The next step is becoming clearer - Q2 review

Klas Palin

2026-08-21

08:25 CEST

The financial position has strengthened, extending the cash runway to Q2 2027e, and we expect the ongoing Phase I study to be completed in Q4. The company has initiated preparations for the next stage of development, which we expect to focus on head and neck cancer, initially targeting the rare indication adenoid cystic carcinoma (ACC). Following the Q2 report, we reiterate our fair value of SEK0.22–0.31 per share.

Undramatic numbers. Opex amounted to SEK8.4m in Q2, with operating cash flow at a similar level of SEK-8.3m. We expect opex to increase moderately in H2 as preparations for the next development phase commence. The rights issue completed during the quarter generated net proceeds of SEK14.9m, bringing the end-Q2 cash position to SEK32.5m, which we estimate is sufficient to fund operations to Q2 2027.

Two more patients before Phase I completion. The final two patients scheduled for fractionated dosing in the ongoing Phase I study have yet to be enrolled, but we expect enrolment shortly following recent regulatory clearance. Supported by encouraging results showing visible Tumorad uptake on SPECT/CT imaging in head and neck cancer patients, the company has become increasingly clear that the next stage of development is likely to focus on adenoid cystic carcinoma (ACC) as the initial target indication. ACC is a rare cancer with significant unmet medical need, and we expect further details on the development strategy later this year.

Estimate changes. We make no material changes to our estimates following Q2. The improvement in EPS is purely mechanical, reflecting the increased share count following the recently completed rights issue.

Valuation unchanged. We maintain our fair value of SEK0.22–0.31 per share following the Q2 report. The main near-term event is the completion of the ongoing Phase I study, which we believe would further de-risk the case.

Sweden

Healthcare

Latest share price

SEK

0.0

-5.00%

18 Nov 2026 15:38 CET

Fair value range

SEK

0.2

—

0.3

22 May 2026

Market cap

SEK

26

m

Key stats

Year

2026e

EPS

-0.05

EPS (Adj.)

-0.05

Sales Growth

-94.97%

EPS Growth (Adj.)

P/E

P/E (Adj.)

EV/EBITA

-0.4

EV/EBITDA

-0.4

Learn more

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB